RLMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Relmada Therapeutics Inc (RLMD) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While there are some positive catalysts such as insider buying and analyst upgrades, the company's financial performance is weak, and there are no strong trading signals or recent news to suggest immediate action. The technical indicators are neutral, and the options data does not show significant bullish sentiment. Therefore, it is better to hold off on investing in this stock right now.
The MACD is positive but contracting, RSI is neutral at 48.971, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 3.803 with resistance at 4.233 and support at 3.373. However, there is no clear breakout or strong trend signal.
Insider buying has increased significantly by 1133.44% over the last month.
Analysts have upgraded the stock with price targets of $8 and $9, citing the potential of the lead asset NDV-01 in addressing a large market opportunity in bladder cancer.
Weak financial performance in Q3 2025, with net income and EPS showing significant declines.
No recent news or event-driven catalysts.
Stock trend analysis indicates a potential decline in the next week (-0.95%) and month (-3.14%).
In Q3 2025, the company reported no revenue growth (0% YoY), a significant drop in net income (-53.55% YoY), and a decline in EPS (-58.33% YoY). Gross margin remains at 0%.
Analysts have a positive outlook on RLMD, with upgrades from Leerink and Jefferies to 'Outperform' and 'Buy' respectively, and price targets of $8 and $9. They highlight the potential of NDV-01 in a competitive but lucrative market.
